Loading...

Tolvaptan, hyponatremia, and heart failure

Tolvaptan is the first FDA-approved oral V(2) receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Zmily, Hammam D, Daifallah, Suleiman, Ghali, Jalal K
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2011
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3108793/
https://ncbi.nlm.nih.gov/pubmed/21694950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S7032
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!